Background: Prognostic models are needed that reflect contemporary practice for men with metastatic castration-resistant prostate cancer (mCRPC). We sought to identify predictive and prognostic variables for overall survival (OS) in chemotherapynaïve men with mCRPC treated with enzalutamide.
Introduction
The majority of men who develop lethal prostate cancer will first develop metastatic castration-resistant prostate cancer (mCRPC) [1] . Despite treatments that improve survival [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] , heterogeneity between patients in disease biology and burden account for significant differences in treatment outcomes.
Prognostic models for survival have been developed and utilized for patient care and clinical trial design [12, 13] . Prior studies identified independent prognostic variables for survival in men with mCRPC treated with docetaxel or abiraterone acetate [13] [14] [15] [16] [17] , including both tumor and host factors. How these prognostic factors together perform in predicting outcomes in chemotherapynaïve mCRPC men treated with the novel androgen receptor (AR)-directed therapies enzalutamide or abiraterone, as is often current practice, is unknown, and validated prognostic models are needed.
Enzalutamide is a second-generation AR inhibitor approved for the treatment of men with mCRPC. In the randomized, phase III PREVAIL trial, enzalutamide significantly reduced the risk of death by 29% [hazard ratio (HR) 0.71; P < 0.001] compared with placebo [2] . By analyzing patients from PREVAIL, we sought to validate and identify novel prognostic and predictive variables associated with survival in chemotherapy-naïve asymptomatic to minimally symptomatic men with mCRPC treated with enzalutamide.
Patients and methods

Patients and study design
The full methodology and results of the international, randomized, doubleblind, placebo-controlled, phase III PREVAIL trial (NCT01212991) have been previously reported (also see supplementary Methods, available at Annals of Oncology online) [2] .
Data sets
The primary end point used for the model was overall survival (OS), using an updated analysis after 784 deaths (46%, data cutoff 1 June 2014) [18] ; all secondary end points used the planned interim data cut at 16 September 2013. Patients from PREVAIL (both enzalutamide and placebo arms) were randomly divided 2 : 1 into the training and testing sets for this analysis (supplementary Figure S1 , available at Annals of Oncology online).
From the data available in the PREVAIL data set, 23 variables were selected for analysis (supplementary Table S1 , available at Annals of Oncology online), based on previous work demonstrating their potential importance in mCRPC outcomes [13, 14, 17, 19, 20] . Skewed data were log transformed or coded as categorical. Correlations were examined using the Spearman correlation method.
Model building
Categorical and/or continuous variables associated with the 23 selected variables with data available in the PREVAIL data set (supplementary Table S1 , available at Annals of Oncology online) were analyzed using stepwise Cox proportional hazards model and adaptive least absolute shrinkage and selection operator (ALASSO), with the hypothesis that results could be considered robust if both methods identified the same or similar sets of variables. Using the training set, 23 variables were analyzed in a stepwise Cox proportional hazards model and a penalized Cox proportional hazards model using ALASSO penalty [2, 21] . The absolute shrinkage property of the ALASSO method results in more stable variable selection [21, 22] . The Akaike Information Criterion (AIC) [23] was used to examine which variables contributed most to the final model. Model building followed a prospectively defined plan in which prognostic discrimination and parsimony were balanced with the need to include variables previously established and validated in the mCRPC setting to maximize generalizability. A predictive treatment interaction term was created for each candidate variable and was tested in the proportional hazards regression model for improvement in OS with enzalutamide relative to placebo.
Model validation
A multivariable Cox proportional hazards model predicting OS using the training set was developed. The HR and 95% confidence interval (CI) were computed for each potentially prognostic variable. Predictive accuracy was assessed in the testing set using time-dependent area under the curve (tAUC) and calibration assessed by plotting the predicted probability of death at 3-month intervals between 6 and 39 months versus observed probability.
A risk score was developed from the multivariable model using the training set. Based on risk scores, the testing set was divided at the median cut point (high-and low-risk groups) and by tertiles (high-, intermediate-, and low-risk groups). The OS in the training and testing sets was analyzed using Kaplan-Meier methodology. In the testing set risk groups, the primary end point of OS and secondary end points of radiographic progression-free survival (PFS) and prostate-specific antigen (PSA)-PFS were analyzed using Kaplan-Meier methodology. Analyses were carried out using SAS software (version 9.4; SAS Institute, Cary, NC) and R glmnet and R survAUC packages, R version 3.2.2 [24] .
Results
Patients
Baseline demographics, medical history, disease characteristics, and distribution of treatment assignments (enzalutamide or placebo) were balanced between the training set (n ¼ 1159) and the testing set (n ¼ 550; supplementary 
Prognostic variable selection
The stepwise model identified 14 prognostic variables for OS, whereas ALASSO identified 13. All variables identified with ALASSO were identified with the stepwise model: albumin, alkaline phosphatase (ALP), Eastern Cooperative Oncology Group performance status, hemoglobin, lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), number of bone metastases, presence of pain, pattern of spread (visceral versus bone versus lymph node only), PSA, time from diagnosis to randomization, treatment (enzalutamide versus placebo), and type of progression at study entry (PSA only versus radiographic). The only variable not identified by ALASSO was de novo metastatic (M1) disease.
Before modeling, we tested for the presence of a treatmentbiomarker interaction with all prognostic variables. Each treatment interaction term was not significant (P > 0.05), indicating that enzalutamide treatment was independently associated with improved survival in all prognostic biomarker-defined groups; thus no predictive biomarkers for enzalutamide efficacy were identified or included in the model.
Given the need for parsimony in model development, we carried out AIC analysis using a stepwise model. The AIC method avoids overfitting, and the decrease in AIC score began to flatten at nine parameters (supplementary Figure S3 , available at Annals of Oncology online), indicating that albumin, LDH, de novo M1 disease, NLR, number of bone metastases, presence of pain, PSA, time from diagnosis to randomization, and treatment were the strongest prognostic variables.
The nine variables identified by AIC analysis did not include visceral pattern of spread, which previously has been demonstrated to be strongly prognostic of survival in men with mCRPC [14, 15, 17, 25, 26] . Likewise, neither ALP nor hemoglobin was included in the AIC analysis, despite their inclusion in the ALASSO and stepwise models and previous validation studies [13, 14] . In our data set, ALP had a moderate correlation with the number of bone metastases, and PSA and hemoglobin had moderate correlation with albumin (supplementary Table S3 , available at Annals of Oncology online). However, to develop a clinically relevant model and potentially improve external validity, we included pattern of spread, ALP, and hemoglobin in our final model. Additionally, because our initial hypothesis was that variables identified by both ALASSO and the stepwise models would be more robust, we opted to remove de novo M1 disease, which was moderately correlated with time from diagnosis (r ¼ À0.49; supplementary Table S3 , available at Annals of Oncology online), a variable captured in both models and AIC analysis. Thus, the final model contained 11 prognostic variables: albumin, ALP, hemoglobin, LDH, NLR, number of bone metastases, presence of pain, pattern of spread, PSA, time from diagnosis to randomization, and treatment. Importantly, our model did not include 12 variables due to lack of statistical significance or model improvement, including type of progression, number of prior secondary hormonal therapies, PSA doubling time, age, baseline corticosteroid use, or prior prostatectomy.
Multivariable model for predicting OS
In a multivariable Cox proportional hazards model performed on the training set, all 11 variables were significantly associated with OS (Table 1) . Concordance for predicting OS as assessed by tAUC score for the 11-variable model was 0.74 in the testing validation set (supplementary Figure S4 , available at Annals of Oncology online).
A risk score was calculated using regression coefficients from the training set for the 11 variables. An algorithm was developed accordingly (supplementary Table S4 , available at Annals of Oncology online) and a nomogram was produced in Figure 1 . Patients in the testing set were stratified as being at high or low risk of death based on median risk score and also stratified as high, intermediate, or low risk based on risk score tertiles. The 11-variable model provided a significant separation between lowrisk and high-risk patients (HR 0.35; 95% CI 0.27-0.46; Figure 2A ) and between low-risk (HR 0.20; 95% CI 0.14-0.29) and intermediate-risk (HR 0.40; 95% CI 0.30-0.53) versus highrisk patients ( Figure 2B ). The full model description is provided in supplementary Table S4 , available at Annals of Oncology online.
Next, we examined the impact of enzalutamide treatment on men in both low-and high-risk prognostic groups of the testing set. Median OS among low-risk patients was NYR with both enzalutamide and placebo, whereas among high-risk patients, median OS was 27.4 and 24.9 months, respectively. Among low-risk patients, median radiographic PFS was 27.5 months with enzalutamide and 8.2 months with placebo (Table 2 ; supplementary Figure S5A , available at Annals of Oncology online) and in high-risk patients, this was 16.6 and 5.3 months, respectively (Table 2 ; supplementary Figure S5A , available at Annals of Oncology online). Median PSA-PFS and radiographic and PSA responses also differed significantly by risk groups (Table 2 ; supplementary Figure S5B , available at Annals of Oncology online).
Risk group development
We examined the utility of categorizing patients into three risk groups based on the number of risk variables from our 11-variable model present at baseline, including enzalutamide or placebo treatment. Clinically relevant cutoffs based on median values or lower limit of normal in the testing set were used for variables with continuous variables (see supplementary Results and Figure S6 , available at Annals of Oncology online, and Table 2 ), which also provided broad discrimination of all clinical outcomes. One-year survival probability Two-year survival probability Three-year survival probability <10 Any liver metastases PSA (ng/ml) Figure 1 . A nomogram is used to assign each of 11 prognostic factors with a point range from 0 to 100 in a graphic interface, based on the estimated regression coefficients from the final multivariable Cox proportional hazards model predicting overall survival (OS). The nomogram results match with the algorithm. The 1-, 2-, and 3-year survival probability versus total points were also generated to allow the clinical partition to predict OS. The nomogram was developed using SAS V R enterprise version 7.1 and is based on the following article: http://support.sas.com/ resources/papers/proceedings13/264-2013.pdf. Instructions to physicians: All of the 11 prognostic factors should be available before using this model. Start from the second top axis by identifying the number of bone metastases. Draw a vertical line to the points axis (top line) to represent the number of prognostic points the patients will receive for number of bone metastases. Do the same for the other prognostic variables. Once all prognostic points for the predictors have been determined, add up the prognostic points for each prognostic variable. On the basis of the total points, one can determine the 1-year survival probability by drawing a vertical line from the total points x-axis to the survival probability. The same process can be performed to estimate the 2-year and 3-year survival probability.
with shorter OS in PREVAIL, reflecting metastatic disease at diagnosis or short duration of castration sensitivity. We validated our 11-variable model in an independent testing data set and demonstrated a high level of prognostic accuracy, similar to clinically useful models previously validated in the docetaxel or postdocetaxel mCRPC treatment settings [13] [14] [15] . In addition, our model provides discrimination for key secondary outcomes in this setting, including PFS, PSA decline, and radiographic response. Interestingly, we did not identify specific predictors of enzalutamide benefit, indicating that enzalutamide improved outcomes regardless of prognostic risk group.
This prognostic model provides several advantages to those previously available because it was developed and validated in a contemporary treatment setting with first-line enzalutamide in chemotherapy-naïve men with mCRPC, reflecting current practice. Although we did not specifically validate our model in men treated with abiraterone, the inclusion of established risk factors and the similar survival times with abiraterone and enzalutamide 
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Median OS, months (95% CI) (7) 6/49 (12) 1/38 (3) 1/15 (7) Partial soft-tissue response, n/N in this setting suggests that this model may provide valuable and generalizable prognostic information to physicians and patients who are treated with first-line novel AR pathway inhibition. Further external validation of this model is critical for generalizability, however. Additionally, we utilized multiple methods for model development and incorporated robust clinical variables previously validated in other treatment settings in the literature, which broadens the clinical applicability of our model. Furthermore, we incorporated enzalutamide and placebo treatment into our model to account for the natural history of mCRPC, which should provide useful information for future clinical trial designs, stratification schemes, and identification of risk groups for trial eligibility and outcome assessments. Finally, our model was developed based on OS, the gold standard end point for regulatory decisions and patient outcomes for mCRPC. Our model is not without limitations. Notably, the PREVAIL data set lacked tissue biopsies, circulating tumor cell (CTC), or cell-free DNA/RNA biomarkers for inclusion in our model. Biomarkers such as CTC enumeration, genomic alterations, AR splice variants, and AR copy number may help better predict survival and should be incorporated into future studies [27] [28] [29] [30] . Despite this, our model identified risk groups with widely differing survival times, illustrating the heterogeneity of outcomes among men with chemotherapy-naïve mCRPC based on readily available clinical parameters.
It should be noted that all validated prognostic models have limitations in informing clinical practice. Although the variables included have strong biologic rationale and independent validation, outcomes for individuals in contemporary practice may differ from those in clinical trial populations, and external validation is recommended in a broader, nontrial population of men with mCRPC. Accordingly, the prognostic model presented in this paper, and in general, should not displace the well-informed clinical judgment of healthcare professionals treating individual patients. However, knowledge of prognosis may aid decisions regarding the aggressiveness with which to pursue active therapy for mCRPC and should help shape trial designs that utilize combinations with AR-directed therapies, using more aggressive approaches for men with high-risk mCRPC who may benefit from combination therapies. We did not incorporate posttreatment PSA declines or radiographic responses in our model, despite their strong associations with survival [14, 20, 31] , in order to develop a purely pretreatment survival model. However, ongoing work is characterizing updated prognosis based on responses after enzalutamide treatment. Finally, early use of abiraterone, apalutamide, and enzalutamide in men with nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer may affect the utility and future generalizability of this model.
The independent prognostic value of NLR was a novel finding that may reflect underlying tumor-associated inflammation or host immune response. Thus, incorporation of NLR, available from a complete blood count with differential, may prove useful for risk stratification in asymptomatic men with mCRPC. Recent data support use of NLR in other cancer settings [32] and, along with albumin and functional status, provide useful measures of host response important in determining long-term survival. Here, we used a cutoff of 2.5 for NLR, similar to that previously evaluated in men with mCRPC [17] , but more relevant in this minimally symptomatic setting.
Conclusion
In summary, our prognostic model was constructed and validated using data routinely collected in chemotherapy-naïve men with mCRPC treated with enzalutamide, identifying subsets of patients with widely differing survival outcomes. This model has potential clinical utility for individual and trial-level survival, potential outcomes prognostication, and clinical trial design of novel treatment approaches in this population.
